SunTrust Banks, Inc. Reiterates Buy Rating for Adaptimmune Therapeutics PLC (ADAP)

Adaptimmune Therapeutics PLC (NASDAQ:ADAP)‘s stock had its “buy” rating reaffirmed by research analysts at SunTrust Banks, Inc. in a report released on Friday. They presently have a $10.00 price target on the biotechnology company’s stock. SunTrust Banks, Inc.’s target price indicates a potential upside of 23.46% from the stock’s current price.

Several other analysts also recently weighed in on the company. ValuEngine raised Adaptimmune Therapeutics PLC from a “strong sell” rating to a “sell” rating in a report on Thursday, July 20th. Leerink Swann reissued an “outperform” rating and issued a $15.00 target price on shares of Adaptimmune Therapeutics PLC in a report on Friday, September 8th. BidaskClub raised Adaptimmune Therapeutics PLC from a “sell” rating to a “hold” rating in a report on Friday, August 25th. Zacks Investment Research downgraded Adaptimmune Therapeutics PLC from a “buy” rating to a “hold” rating in a report on Monday, July 17th. Finally, TheStreet raised Adaptimmune Therapeutics PLC from a “d” rating to a “c” rating in a report on Thursday, November 2nd. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $11.58.

Adaptimmune Therapeutics PLC (NASDAQ:ADAP) opened at $8.10 on Friday. Adaptimmune Therapeutics PLC has a 1 year low of $3.76 and a 1 year high of $9.29.

ILLEGAL ACTIVITY NOTICE: “SunTrust Banks, Inc. Reiterates Buy Rating for Adaptimmune Therapeutics PLC (ADAP)” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/11/12/suntrust-banks-inc-reiterates-buy-rating-for-adaptimmune-therapeutics-plc-adap.html.

Several institutional investors have recently bought and sold shares of ADAP. Matrix Capital Management Company LP purchased a new stake in shares of Adaptimmune Therapeutics PLC in the 2nd quarter valued at about $39,027,000. Baillie Gifford & Co. raised its stake in shares of Adaptimmune Therapeutics PLC by 43.7% during the 2nd quarter. Baillie Gifford & Co. now owns 1,323,308 shares of the biotechnology company’s stock worth $5,941,000 after buying an additional 402,324 shares in the last quarter. Renaissance Technologies LLC raised its stake in shares of Adaptimmune Therapeutics PLC by 75.4% during the 1st quarter. Renaissance Technologies LLC now owns 780,800 shares of the biotechnology company’s stock worth $4,302,000 after buying an additional 335,700 shares in the last quarter. Artal Group S.A. raised its stake in shares of Adaptimmune Therapeutics PLC by 66.7% during the 3rd quarter. Artal Group S.A. now owns 500,000 shares of the biotechnology company’s stock worth $4,095,000 after buying an additional 200,000 shares in the last quarter. Finally, Balyasny Asset Management LLC purchased a new position in shares of Adaptimmune Therapeutics PLC during the 2nd quarter worth approximately $846,000. 68.12% of the stock is owned by institutional investors and hedge funds.

Adaptimmune Therapeutics PLC Company Profile

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.

Receive News & Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply